Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01047540 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2
A Phase 2 study of HSV-2, sponsored by AiCuris Anti-infective Cures.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
- 6
- Study locations
NCT01047540 is a Phase 2 study of HSV-2 that has completed, run by AiCuris Anti-infective Cures. The registered enrollment target is 156 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT01047540, a Phase 2 study of HSV-2, has completed, sponsored by AiCuris Anti-infective Cures.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
- 6
- Study locations
Study Summary
The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AIC316
Study Locations (6)
Florida
- Cetero Research Miami Gardens - Miami
Indiana
- Indiana University School of Medicine, Office for Research - Indianapolis
Oregon
- Westover Heights Clinic - Portland
Texas
- University of Texas Health Science Centre, Center for Clincial Studies - Houston
Utah
- University of Utah - Salt Lake City
Washington
- University of Washington, Virology Research Clinic - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01047540
The ClinicalTrials.gov registry entry for NCT01047540 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AiCuris Anti-infective Cures, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HSV-2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01047540 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Florida, Indiana, Oregon.
Frequently Asked Questions
What is clinical trial NCT01047540 about?
NCT01047540 is a clinical study titled "Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2". The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes
What is the current status of trial NCT01047540?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2010-03. Estimated completion is 2011-03.
What conditions does trial NCT01047540 study?
This clinical trial studies the following conditions: HSV-2.
What interventions are being tested in trial NCT01047540?
The interventions under investigation include: Placebo (DRUG), AIC316 (DRUG).
Who is sponsoring clinical trial NCT01047540?
This trial is sponsored by AiCuris Anti-infective Cures, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01047540 being conducted?
This trial has 6 study locations across Florida, Indiana, Oregon, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.